Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b/2a Study to Evaluate the Safety of CMTX-101 in Combination with Inhaled Antibiotics in People with Cystic Fibrosis Chronically Infected with Pseudomonas Aeruginosa

Trial Profile

A Phase 1b/2a Study to Evaluate the Safety of CMTX-101 in Combination with Inhaled Antibiotics in People with Cystic Fibrosis Chronically Infected with Pseudomonas Aeruginosa

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 20 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CMTX 101 (Primary)
  • Indications Pseudomonal infections
  • Focus Adverse reactions
  • Sponsors Clarametyx Biosciences

Most Recent Events

  • 16 Jun 2025 According to Clarametyx Biosciences media release, the full study enrollment is expected by end of 2025.
  • 16 Jun 2025 Interim Results(n=21) presented in the Clarametyx Biosciences media release.
  • 28 Jan 2025 According to Clarametyx Biosciences media release, has received investment from the Kineticos AMR Accelerator Fund, extending its Series A funding round from 2024. This investment will support the company's pipeline, including the ongoing CMTX-101 trial.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top